CTX-10726

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameCTX-10726
Drug Alias NameCTX-10726
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 modulatorsVascular endothelial growth factor A modulators
TargetsProgrammed cell death protein 1Vascular endothelial growth factor A
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsEsophageal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPreclinical
Originator CompaniesCompass Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCompass Therapeutics LLCCompass Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsEsophageal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A